Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT05176080
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 368
- Registration Number
- NCT05169567
- Locations
- 🇨🇳
Taipei Tzu Chi General Hospital, New Taipei City, Taiwan
🇩🇰Regionshospitalet Gødstrup, Herning, Midtjylland, Denmark
🇭🇺Bacs-Kiskun Megyei Korhaz, Kecskemét, Bács-Kiskun, Hungary
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
- Conditions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Dr. Reddy's Laboratories SAS
- Target Recruit Count
- 40
- Registration Number
- NCT05140655
- Locations
- 🇨🇴
SOHEC, Valledupar, Cesar, Colombia
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sarah K. Lynam MD
- Target Recruit Count
- 31
- Registration Number
- NCT05113368
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 19
- Registration Number
- NCT05101564
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05090358
- Locations
- 🇺🇸
Ohio State University (Data Collection & Data Analysis), Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT05082025
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 37
- Registration Number
- NCT05076695
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.